NPR reports on a "mix and match" strategy in the UK, technically known as heterologous vaccination. Researchers are studying whether combining different vaccine types, such as a viral vector (AstraZeneca) followed by an mRNA vaccine (Pfizer/Moderna), produces a stronger immune response. This marks a shift from previous guidance against mixing brands.
